Filing Details

Accession Number:
0001225208-22-012842
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-15 16:34:45
Reporting Period:
2022-12-13
Accepted Time:
2022-12-15 16:34:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
200406 Johnson & Johnson JNJ Pharmaceutical Preparations (2834) 221024240
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1744564 J Joseph Wolk One Johnson &Amp; Johnson Plaza
New Brunswick NJ 08933
Exec Vp, Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-04-20 18 $0.00 35,840 No 5 G Direct
Common Stock Disposition 2022-04-20 28 $0.00 35,812 No 5 G Direct
Common Stock Acquisiton 2022-12-13 12,926 $90.44 48,738 No 4 M Direct
Common Stock Acquisiton 2022-12-13 1,855 $72.54 50,593 No 4 M Direct
Common Stock Disposition 2022-12-13 1,855 $179.46 48,738 No 4 S Direct
Common Stock Disposition 2022-12-13 12,926 $179.62 35,812 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 G Direct
No 5 G Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Options (Right to Buy) Disposition 2022-12-13 1,855 $0.00 1,855 $72.54
Common Stock Employee Stock Options (Right to Buy) Disposition 2022-12-13 12,926 $0.00 12,926 $90.44
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-01-17 2023-01-13 No 4 M Direct
0 2017-02-11 2024-02-09 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,988 Indirect By 401k
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $179.610 to $179.670. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. Stock Fund Dividends Accrued: Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (11/30/2022)